Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000338

Enrollment

Unknown

Registered

2009-02-23

Start date

2009-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Group A:Full dose of RASS blockade (ACEI and ARB blocker)

Group B:prednisone

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. biopsy-proven IgA nephropathy; 2. proteinuria (protein, 1.5 to 3 g/d); 3. eGFR>30ml/min/1.75m2; 4. Age 18-70 years; 5 Hypertention or untreated blood pressure >130/80mmHg.

Exclusion criteria

Exclusion criteria: 1. Secondary IgA nephropathy; 2. Pathology-proven crecsentic glomerulonephritis.

Design outcomes

Primary

Measure	Time frame
Concentration of serum creatinin;	—

Secondary

Measure	Time frame
Quantitative Urinary protein in 24 hours;	—

Countries

China

Contacts

Public ContactChen Jianghua

chenjianghua@zju.edu.cn+86 0571 87236189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026